HAART adherence barriers similar across settings and countries

Sleeping when a dose is required can be a barrier to HAART adherence |
Barriers to adherence to highly active antiretroviral therapy (HAART) are largely consistent across multiple settings and countries, a recent study suggests (PLoS Medicine 2006;3[11]:e438).
The study — a systematic review of 37 qualitative studies and 47
surveys (with a quantitative methodology), of which 12 were conducted
in developing nations — found that the following important barriers
to adherence were reported across the board: fear of disclosure of HIV
status; concomitant substance misuse; forgetfulness; suspicions of treatment;
too complicated regimens; number of pills required; decreased quality
of life; work and family responsibilities; sleeping at the time a dose
is required; and access to medicines.
Sonali Sonecha, lead pharmacist HIV services, North Middlesex Hospital,
speaking on behalf of the HIV Pharmacy Association, said that the study
offers a good starting point for considering what the true barriers to
treatment adherence might be, enabling pharmacists to develop strategies
to overcome such barriers. Ms Sonecha said that, although more antiretroviral
drugs have become available over the past three to four years, treatment
has become simpler to take (eg, fewer pills, fewer food restrictions). “HIV
is now viewed as a chronic illness and patients can expect to be on regular
drug treatment for many years,” she pointed out.
“Whereas before,” she said, “the focus would have been
on giving practical advice on managing complex regimens, now pharmacists
are involved in supporting patients in maintaining good adherence over
a long period of time.”
According to the study, patients in developed nations identified important
facilitators to adherence as: having a sense of self-worth; seeing positive
effects of antiretrovirals; accepting their HIV seropositivity; understanding
the need for strict adherence; making use of reminder tools; and having
a simple regimen. |